OKYO Pharma Ltd (LSE: OKYO, NASDAQ: OKYO), a biopharmaceutical company focused on ophthalmology, is set to present two papers on their treatment for dry eye disease (DED), OK-101, at the American Society of Cataract and Refractive Surgery (ASCRS 2023) in San Diego, California, from May 5-8.
The presentations will be delivered by Dr. Pedram Hamrah, a renowned expert on DED and corneal neuropathic pain, who serves as the co-director of the Cornea Service and director of the Center for Translational Ocular Immunology at the New England Eye Center at Tufts Medical Center.
The papers will focus on pre-clinical and animal model data, demonstrating the effectiveness of OK-101 in treating DED and Neuropathic Corneal Pain (NCP). OK-101 is a potential breakthrough treatment aimed at addressing the significant unmet need in the multi-billion-dollar market for DED.
